Blockchain Registration Transaction Record

Clene Inc. Innovates Breakthrough Oral Nanotherapeutic for Neurodegenerative Diseases

Clene Inc. has developed CNM-Au8(R), an oral nanotherapeutic designed to revitalize the brain’s mitochondrial function, representing a significant advancement in the treatment of neurodegenerative diseases.

This news matters as it represents a significant advancement in the treatment of neurodegenerative diseases, offering potential improvements in movement, speech, and overall function for patients. The breakthrough has the potential to significantly improve survival and quality of life for those with neurodegenerative diseases, and Clene Inc. is working towards regulatory approvals to bring this groundbreaking treatment to market.